Please login to the form below

Not currently logged in

Roche drug gets NICE recommendation

Roche has announced that the National Institute of Clinical Excellence has recommended its drug, NeoRecormon
Roche has announced that the National Institute of Clinical Excellence (NICE) has recommended its drug, NeoRecormon.

It has been developed for the treatment of chemotherapy-induced anaemia and will be used in combination with intravenous iron. NeoRecormon is one of many erythropoietic proteins (EPOs) that have been given NICE authorisation that can be prescribed to women suffering from low levels of blood after undergoing chemotherapy for ovarian cancer.

Dr Paul Cornes, consultant clinical oncologist at the Bristol Haematology and Oncology Centre, said: "The positive NICE guidance for EPOs offers women with ovarian cancer who are treated with platinum-based chemotherapy another option which could improve their quality of life, help conserve scarce blood resources and reduce the risk of transfusion associated infection."

Symptoms of chemotherapy-induced anaemia include severe fatigue which can significantly affect a patient's standard of living and their ability to perform normal daily tasks. Nurses have reported that some patients elect to discontinue their chemotherapy because of the crippling side effects and the impact they can have on their life.

Blood transfusions are currently the only way to treat chemotherapy-induced anaemia but the number of blood donors are decreasing, forcing clinicians and researchers to find alternative methods. NeoRecormon and other EPOs could prove to be a step forward in helping women going through arduous chemotherapy regimens for ovarian cancer.

28th May 2008


Featured jobs

Subscribe to our email news alerts


Add my company
Swordfish Advertising

At Swordfish Advertising, we believe building an effective brand shouldn't be stressful. Don't get us wrong; it takes blood, sweat...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...